Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
When faced with surprise expenses, pause, assess impact, and execute a prepped plan: reallocate, delay nonessential spending, and access the buffer.
10,028 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
The latest consumer sentiment 56.4 reading sets the tone for retail stocks and the VanEck Retail ETF (RTH) in 2026. I...
Banks mobilize to derail the CLARITY Act as lawmakers prepare a Senate markup next week, signaling a tense clash over...
After the first quarter, the sharkninja 2026 earnings call reveals a company balancing strong demand with cost pressu...
A reality TV moment on a political landmark becomes a money lesson. This article breaks down pricing psychology, how ...
The Trade Desk faced a tougher path after missing Q1 revenue and guiding for a weaker Q2, triggering multiple downgra...
AMD has surged dramatically, up 320% over the past year, sparking questions about whether investors should shift focu...
Dream Finders' unsolicited cash offer values Beazer at about $704 million, sparking a public contest as U.S. homebuil...
HF Foods (HFFG) faces a pivotal year as Q1 2026 results unfold. This guide breaks down what to watch, how to interpre...
April data show mortgage credit availability tightened after three months of easing, led by conventional loans. Gover...
Binance’s delisting of five smaller tokens sparked a brutal price collapse altcoins, with double-digit losses across ...
The bitcoin outflows just 3-month window intensified Friday, with a $635 million pull on May 13 led by BlackRock’s IB...